Finland· FI-REL-REL65515
Qarziba
A dinutuximab beta product containing dinutuximab beta, registered in Finland by Abacus Medicine A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Dinutuximab beta is registered in 11 of 19 countries.
Countries holding a registration under ATC L01FX06 (dinutuximab beta), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Dinutuximab beta · ATC L01FX06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Fimea (Finland)- Active substance
- Dinutuximab beta
- Manufacturer
- Abacus Medicine A/S
- Country
- Finland (FI)
- ATC code
- L01FX06
- ATC class
- Dinutuximab beta
- Defined daily dose
- 2.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
183 interactions on record for dinutuximab beta.
Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dinutuximab beta · interactions on record
183 records
- 54 severe
- 129 moderate
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dinutuximab beta in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumQarziba 4.5 mg/mlRecordati Netherlands
- CzechiaQARZIBARecordati Netherlands B.V., Schiphol-Rijk
- IrelandQarziba 4.5 mg/mL concentrate for solution for infusionEUSA Pharma (Netherlands) B.V.
- IcelandQarzibaRecordati Netherlands B.V.
- NorwayQarzibaRecordati Netherlands B.V.
- PolandQarzibaRecordati Netherlands B.V.
- SwedenQarziba 4,5 mg/mL Koncentrat till infusionsvätska, lösningRecordati Netherlands B.V
- United StatesUnituxinUnited Therapeutics Corporation
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Qarziba
- Liechtenstein · Qarziba
- Norway · Qarziba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/15ca7275-748b-4b72-9904-74cbb1d45e00 GET /v1/drugs/15ca7275-748b-4b72-9904-74cbb1d45e00?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "4.5 mg/ml",
"atc_label": "dinutuksimabi beeta",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/17/1191/001",
"fimea_rel_id": "REL65515",
"authorised_at": "2026-07-31"
}See everything about dinutuximab beta.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.